Indication
Stage IIIA Skin Melanoma
3 clinical trials
4 products
3 drugs
Clinical trial
A Randomized Phase 2 Study of Rituxan Hycela in Patients With Advanced Melanoma Undergoing Combination Immune Checkpoint Blockade With Nivolumab and IpilimumabStatus: Active (not recruiting), Estimated PCD: 2024-09-13
Product
NivolumabProduct
IpilimumabClinical trial
A Phase I Study to Evaluate the Safety of Trigriluzole (FC-4157/BHV-4157) in Combination With PD-1 Blocking AntibodiesStatus: Completed, Estimated PCD: 2022-10-20
Product
Enzyme InhibitorDrug
T-VECDrug
mFOLFOX6Clinical trial
Trial of Interleukin-2 in Combination With Pembrolizumab for Patients With Unresectable or Metastatic MelanomaStatus: Terminated, Estimated PCD: 2018-10-18
Drug
interleukin-2